Načítá se...
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
Evolocumab has been shown to consistently reduce low-density lipoprotein cholesterol (LDL-C) across populations. The phase 3 studies included administration in the home-use and in-clinic settings but did not specifically evaluate the feasibility of home-use administration. Two clinical studies enrol...
Uloženo v:
Vydáno v: | Springerplus |
---|---|
Hlavní autoři: | , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Springer International Publishing
2016
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4783317/ https://ncbi.nlm.nih.gov/pubmed/27066336 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-1892-3 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|